Biodesix/Aveo: A Harbinger Of Deals To Come
Executive Summary
Aveo Pharmaceuticals and Biodesix have entered into a worldwide agreement to develop and commercialize Aveo’s ficlatuzumab, an antibody that inhibits hepatocyte growth factor, using Biodesix’s serum-based companion diagnostic VeriStrat, which guides treatment decisions for patients with advanced non-small cell lung cancer.
You may also be interested in...
When Illumina Buys Roche: The Dawning Of The Era Of Diagnostics Dominance
With current technology and resources, a well-funded in vitro diagnostics company can create and pursue a strategy of information gathering and informatics application to create medical knowledge, enabling it to assume the risk and manage certain segments of patients. But few if any pharma or diagnostics firms appear poised to take advantage.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.